BioXcel Therapeutics (BTAI) Other Accumulated Expenses (2018 - 2026)

BioXcel Therapeutics' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 454.85% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (up 454.85% YoY), while the FY2025 annual figure was $622000.0, up 93.17% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $2.3 million, up from $622000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $2.3 million in Q1 2026, with the low at $152000.0 in Q1 2022.
• The 5-year median for Other Accumulated Expenses is $366000.0 (2025), against an average of $512235.3.
• The sharpest annual moves came in 2023 and 2026: Other Accumulated Expenses sank 78.41% in 2023, then surged 454.85% in 2026.
• BioXcel Therapeutics' Other Accumulated Expenses stood at $820000.0 in 2022, then tumbled by 78.41% to $177000.0 in 2023, then soared by 81.92% to $322000.0 in 2024, then soared by 93.17% to $622000.0 in 2025, then jumped by 277.33% to $2.3 million in 2026.
• Business Quant data shows BTAI's Other Accumulated Expenses at $2.3 million in Q1 2026, $622000.0 in Q4 2025, and $450000.0 in Q3 2025.